Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow OS Therapies Inc

Get SEC filing alerts via email and in your feed for OS Therapies Inc

OSTX

OS Therapies Inc

About OS Therapies Inc

OS Therapies Inc. is a biopharmaceutical company developing innovative immunotherapies and targeted treatments for osteosarcoma and other solid tumors. Its pipeline includes OST-HER2, an immunotherapy for rare cancers, and OST-tADC, a tunable antibody-drug conjugate platform targeting multiple cancers. The company focuses on clinical-stage development, leveraging proprietary technology, strategic collaborations, and regulatory designations to address unmet medical needs in oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from OS Therapies Inc

1
1
OS Therapies Inc OS Therapies Reports $10.4 Million Net Loss and Increased R&D Spending in Latest 10-Q Filing

Via official filing (AI summary) | 17 days ago | 0 comments

2
1
OS Therapies Inc OS Therapies Reports Increased Operating Expenses and Net Loss in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
OS Therapies Inc OS Therapies Reports $6.9 Million Net Loss and Expands Operations with HER2 Asset Acquisition

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
OS Therapies Inc OS Therapies Reports Increased Losses and Growth in Assets in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
OS Therapies Inc OS Therapies Reports Increased Net Loss and Operating Expenses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
OS Therapies Inc OS Therapies Reports $8.9 Million Net Loss for 2024, Highlights IPO Success and Clinical Trial Progress

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
OS Therapies Inc OS Therapies Reports Improved Liquidity, Increased Expenses, and Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments